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ABSTRACT 
The aim of this study was the design and evaluation of a novel plasma stable, pH-sensitive niosomal 
formulation of Mitoxantrone by a modified ethanol injection method. Cholesterol hemisuccinate was 
added instead of cholesterol in order to produce pH-sensitivity property and using PEG-Poly 
(monomethyl itaconate)-CholC6 (PEG-PMMI-CholC6) copolymer introduced simultaneously pH-
sensitivity and plasma stability properties in prepared niosomes. The pH-sensitivity and cytotoxicity of 
Mitoxantrone niosomes were evaluated in vitro in phosphate buffer with different pHs as well as using 
human ovarian cancer cell line (OVCAR-3), human breast cancer cell line (MCF-7) and human umbil-
ical vein endothelial cells (HUVEC). Results showed that both cholesterol derivatives bearing formu-
lations had pH-sensitive property and were found to release their contents under mild acidic conditions 
rapidly. In addition, the PEG-PMMI-CholC6-based niosomes could reserve the pH-sensitivity after 
incubation in plasma. Both Mitoxantrone-loaded pH-sensitive niosomes showed higher cytotoxicity 
than the conventional niosomes on OVCAR-3 and MCF-7 cell lines. However, both pH-sensitive nio-
somes exhibited lower cytotoxic effect on HUVEC cell line. Plasma stable, pH-sensitive niosomes 
could improve the cytotoxic effect and reduce the side effects of anti-tumor drugs. 
 
Keywords: pH-sensitive plasma stable niosome, cytotoxic effect, Mitoxantrone 
 
 
 
INTRODUCTION 
The ability to deliver drugs much more 
effectively and efficiently to the site of inter-
est resulted in less harmful side effects and 
more valuable therapeutic actions, particular-
ly in cancer treatment. High drug toxicity is 
a drawback for dose of chemotherapeutics, 
because side effects limit the drug dosage 
that can be administered (Hrushesky et al., 
1992; Wong et al., 2007). Vesicles are prom-
ising carriers employed to deliver chemo-
therapeutic agents, antisense oligonucleo-
tides and genes to various therapeutic tar-
gets, specifically (Chen et al., 2010; Gabizon 
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et al., 2004; Mamot et al., 2003; Petersen et 
al., 2012). However, significant progress in 
overcoming many of the original obstacles 
for effective delivery of these agents has 
been limited. Different triggered release 
mechanisms have been designed for vesicles 
in order to promote drug concentrations in 
target tissues or cell compartments. These 
stimuli, including temperature light, enzy-
matic degradation and ultrasound have been 
efficiently used to initiate the breakdown of 
the bilayers (Akamatsu, 2009; Cho et al., 
2009; Park et al., 2013; Torchilin, 2009; 
Zhou et al., 2012; Zignani et al., 2000). 
Many pH-sensitive systems are based on pH-
responsive peptides or proteins that can effi-
ciently trigger membrane fusion/disruption at 
acidic pH. Despite their interesting features, 
their clinical application may be limited due 
to potential immunogenicity. Another target-
ing strategy usually involves conjugation of 
vesicles with antibodies or other ligands. 
However, these methods have limitations 
due to the heterogeneous expression of the 
target receptors in diseased tissues. One of 
the common characteristics of diseased tis-
sues (cancerous tumors, inflammation, in-
fected areas, ischemia, arthritis, and athero-
sclerosis) is low pH in extracellular envi-
ronment (Aojula et al., 2002; Koren et al., 
2012; Negussie et al., 2010; White et al., 
1995; Yuba et al., 2013). The concept of pH-
sensitive vesicles arises from the fact that 
certain enveloped viruses developed strate-
gies to take advantage of the acidification of 
the endosomal lumen to infect cells, as well 
as from the observation in some pathological 
tissues. Recently, considerable efforts have 
been made to develop vesicles which are sta-
ble under normal physiological conditions 
but become destabilized and release their 
contents in acidic environment of tumor tis-
sues, which is slightly acidic compared to 
healthy tissues. This enables the drug to be 
released selectively and specifically with 
greater efficiency from pH-sensitive vesicles 
in target sites and reduces side effects 
(Carafa et al., 2006; Van den Bossche et al., 
2011; Yatvin et al., 1987; Zhelev and 
Needham, 2002). 
Different classes of pH-sensitive vesicles 
have been proposed in the literature. The 
most commonly recognized concept involves 
the combination of phosphatidylethanola-
mine or its derivatives. In recent times, the 
use of novel pH-sensitive lipids, synthetic 
fusogenic peptides either encapsulated or 
incorporated in the lipid bilayer, and associa-
tion of pH-sensitive polymers with vesicles, 
have been reported (Koutroumanis et al., 
2013; Sezaki et al., 1989; Sułkowski et al., 
2005; Weiner, 1989). 
Recently the well modified polymers 
strategy was developed to improve targeting 
ability. Many polymers were investigated so 
far for the design of pH-sensitive vesicles 
based on poly(alkyl acrylic acid)s, succinyl-
ated PEG, biodegradable polyphosphazenes 
and N-isopropylacrylamide copolymers 
(Huynh et al., 2009; Koutroumanis et al., 
2013; Luo and Jiang, 2012; Salgado-
Rodrı́guez et al., 2004; Yessine et al., 2003). 
Although the pH-sensitive vesicles are 
very promising as a drug carrier, however, 
the lack of stability in blood and the short 
blood circulation time of pH-sensitive vesi-
cles have remained as major drawbacks for 
their application in vivo. Recently, inclusion 
of polyethylene glycol (PEG)-derived lipids 
in vesicular bilayers has been shown that 
they are capable of inhibiting the rapid up-
take of vesicles by the reticuloendothelial 
system which results in much longer in-vivo 
circulation half-life. A main concern for pH-
sensitive vesicles or any other polymer de-
rivatives is the detrimental effect of PEGyla-
tion on the pH-sensitivity. Another issue re-
garding polymer-coated vesicles is their par-
tial loss of pH-responsiveness following in-
cubation in biological fluids. Protein adsorp-
tion on the pH-sensitive vehicles may stabi-
lize the system and/or extract the copolymer 
from the lipid bilayers partially (Ducat et al., 
2011; Felber et al., 2012; Ishida et al., 2006; 
Løkling et al., 2003; Sudimack et al., 2002). 
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Mitoxantrone (MTO) has been used ex-
tensively as a component of chemotherapeu-
tic regimens for a number of fatal diseases, 
including leukemia, lymphoma, cancers of 
the breast and prostate, and to treat multiple 
sclerosis. However, MTO has been reported 
to provide only limited clinical benefit in in-
traperitoneal chemotherapy due to severe 
systemic toxicity, notably dose-related car-
diotoxicity. Various delivery systems have 
been developed to reduce the dose-limiting 
systemic toxicities of MTO, including MTO-
eluting beads and solid lipid nanoparticles. It 
has two physiologically dissociated groups 
(pKa values: 8.13 and 5.99) and it is soluble 
in water in spite of its lipophilicity (log P, 
0.7) (Law et al., 1996; Li et al., 1995; 
Neuhaus et al., 2005). 
For decades, several vesicular systems 
have been studied as a potential system for 
delivering several different anticancer drugs. 
In this study we prepared plasma stable, pH-
sensitive niosomes in order to improve cyto-
toxicity and selectivity of Mitoxantrone. 
 
MATERIALS AND METHODS 
Materials 
Mitoxantrone was obtained from Sigma-
Aldrich Company (USA). Cholesterol (Chol) 
was obtained from Merck Company (Ger-
many) and cholesterol hemisuccinate 
(CHEMS) was supplied from Sigma-Aldrich 
Company (USA). Cholesterol derivative 
(PEG-PMMI-CholC6) was synthesized in 
our group. Thiazolyl blue tetrazolium bro-
mide (MTT), L-glutamine, penicillin, strep-
tomycin, dimethyl sulfoxide and Sorenson 
buffer were obtained from Sigma-Aldrich 
(USA). RPMI-1640 medium and fetal bovine 
serum (FBS) were purchased from Gibco 
Company (USA). All solvents were HPLC 
grade and all other chemicals were analytical 
grade from Merck Company (Germany). 
 
METHODS 
Synthesis of cholesterol derivative 
The PEG-PMMI-CholC6 copolymer was 
synthesized according to our previously pub-
lished methods (Bagheri et al., 2013). Syn-
thesis pathway of PEG-PMMI-CholC6 co-
polymer was shown schematically in Figure 1. 
 
 
Figure 1: Synthesis pathway of PEG-PMMI-CholC6 copolymer 
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Niosome preparations 
Niosomes were prepared by a method 
which was modified and described previous-
ly (Ghanbarzadeh et al., 2013c). Ingredients 
were dissolved in methanol/chloroform mix-
ture in a 250 mL round-bottom flask and 
dried in a rotary evaporator under low pres-
sure at 37 ºC to form a thin film on the flask. 
The Mitoxantrone aqueous solution (PBS pH 
7.4) was added to the flask. Niosomes were 
formed by constant vortexing for 30 min and 
sonicated for 10 min in a bath sonicator. 
Prepared niosomes were subsequently ex-
truded through polycarbonate filters (Milli-
pore, USA) with a pore size of 100 nm using 
a handheld Mini Extruder (Avanti Polar Li-
pids Inc.). 
 
Particle size and zeta potential  
measurement 
Prepared niosomes were stored at 4 °C 
and ambient temperature for 3 months. Sam-
ples were taken on for analysis of particle 
size (PS) and zeta potential. For determina-
tion process, each sample was dispersed in 
PBS (pH 7.4) to a final volume of 10 mL and 
its particle size and zeta potential were ana-
lyzed using a Zetasizer (Malvern, UK). 
 
Determination of the entrapped efficiency  
Dialysis tubes were employed for separa-
tion of un-entrapped drug during 24 hrs at 10 
ºC. Residual drug content in niosomes was 
considered as encapsulated drug and encap-
sulation efficiency was measured after inter-
ruption of niosomes by methanol and meas-
urement of the MTO quantity 
(Ghanbarzadeh and Arami, 2013b). 
Encapsulation efficiency percent (EE%) 
was calculated using the following equation: 
EE (%) = [(Ctotal–C free)/Ctotal] ×100. 
 
In vitro drug release 
One milliliter of each niosomal formula-
tion was placed in the dialysis tube contain-
ing polycarbonate membrane (cut-off: 100 
nm) stirring (rpm=50) in a beaker containing 
50 mL (37 °C) of phosphate buffer solution, 
and was adjusted to two pH values (pHs 6.5 
and 7.4) (Ghanbarzadeh and Arami, 2013a). 
At predetermined time intervals, 2 mL of the 
dissolution medium was withdrawn from re-
ceiver compartment and drug content was 
measured spectrophotometrically (Ghanbar-
zadeh and Arami, 2013a). The same volume 
of fresh pre-warmed dissolution medium was 
replaced to keep the volume constant. 
 
Physicochemical stability of niosomes 
The stability of prepared niosomes was 
assessed in the case of particle size, zeta po-
tential, encapsulation efficiency percent and 
remained drug at 4 °C and ambient tempera-
ture monthly over a period of three months. 
 
Niosome plasma stability  
Particle size, drug leakage and stability 
of pH-sensitivity property of MTO-loaded 
niosome were evaluated after incubation in 
plasma (50:50 v:v) for 1 hr at 37 °C. 
 
Cell lines 
Cytotoxicity of prepared niosomes was 
assessed on the human breast cancer cell line 
(MCF-7), human ovarian cancer cell line 
(OVCAR-3) and on the human umbilical 
vein endothelial cells (HUVEC) (Obtained 
from Pasteur Inst. (Tehran, Iran). The cells 
were cultured in RPMI-1640 medium rou-
tinely, supplemented with 10 % fetal bovine 
serum, 100 U/mL penicillin G and 100 U/mL 
streptomycin, and incubated in 5 % CO2 at 
37 °C subsequently. Subconfluent monolayer 
cells were detached from the culture T-75 
flask by trypsin treatment and resuspended in 
the fresh RPMI-1640 medium. Cells were 
seeded at a density of 1×10
4
 cells per well in 
96-well flat bottom plates with a final vol-
ume of 200 μL.  
 
Cytotoxicity study 
To determine cytotoxicity activity of nio-
somal formulations, the cell viability assay, 
MTT (Thiazolyl blue tetrazolium bromide, a 
yellow tetrazole) assay, was employed. 
Briefly, MCF-7, OVCAR-3 and HUVEC 
cells were seeded in 96-well plate containing 
RPMI-1640 medium and subsequently incu-
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bated overnight. After this period, cells were 
treated with MTO-loaded conventional nio-
somes and two types of pH-sensitive nio-
somes at three concentrations (50, 100 and 
200 µmol/L) for 72 hrs. Then, the incubation 
medium was replaced with 200 μL of fresh 
medium containing MTT (2 mg/mL). After 
incubation for extra 4 hrs at 37 °C, the cul-
ture medium containing MTT was removed 
and then 200 μL of DMSO: Sorencene buffer 
(8:1) was added to each well. Cell viability 
was detected by reading the absorbance of 
each well at 570 nm using a microplate read-
er after 15 min of shaking (Biotek, ELx 800, 
USA).  
 
Statistical analysis 
Data analysis was performed using SPSS 
software (version 17). Analysis of variance 
(ANOVA) was employed for comparison of 
the difference among the groups. Data was 
expressed as Mean ± Standard Deviation and 
the P-value < 0.05 was considered as signifi-
cance level.  
 
RESULTS AND DISCUSSION 
Preparation and characterization of  
niosomes 
Table 1 shows the composition of con-
ventional and two types of pH-sensitive nio-
somes. These are optimized formulations 
which were obtained after our preliminary 
studies and experimental design. Immediate-
ly after preparation of niosomes, particle 
size, zeta potential and entrapment efficiency 
percent of three types of niosomes were in-
vestigated and presented in Table 2.  
Mean particle sizes of conventional, 
CHEMS-based niosomes and PEG-PMMI-
CholC6 bearing niosomes were 186.3 ± 26.3, 
156.6 ± 16.3 and 168.3 ± 22.6 nm which did 
not show a significant difference among 
formulations. The particle size distribution 
was also showed a mono-modal distribution 
with low polydispersity index (data not 
shown). Encapsulation efficiency percent of 
prepared niosomes was fairly high and was 
found in the range of 70.9-73.2 % where 
there was not any significant difference 
among three noisome types. The zeta poten-
tial value of niosomal preparation is related 
to the stability of niosomes. Regarding the 
zeta potential of prepared niosomes, the zeta 
potential value of PEG-PMMI-CholC6 bear-
ing pH-sensitive niosomes was significantly 
lower than pH-sensitive niosomes containing 
CHEMS and conventional niosomes, and 
zeta potential value slightly shifted towards 
neutral (-12.1 ± 0.9 mV). The lower zeta po-
tential may be attributed to the PEG layer
 
 
Table 1: Composition of different types of prepared niosomes [Cholesterol (Chol), PEG-PMMI-
CholC6, Tween 60 and cholesterol hemisuccinate (CHEMS) (µmol/mL)]  
Niosome type Tween 60 Chol PEG-PMMI-
CholC6 
CHEMS 
Conventional 4 4 - - 
pH-sensitive (CHEMS) 4 - - 4 
pH-sensitive (PEG-PMMI-CholC6) 4 - 4 - 
 
 
Table 2: Characteristics of different type of niosomes  
Niosome type Particle size 
(nm) ± SD 
Polydispersity 
index ± SD 
Zeta potential 
(mV) ± SD 
Encapsulation  
efficiency (%) ± SD 
Conventional 186.3 ± 26.3 0.25 ± 0.3 -20.6 ± 0.3 71.9 ± 2.3 
pH-sensitive (CHEMS) 156.6 ± 16.3 0.23 ± 0.2 -16.6 ± 0.5 73.2 ± 1.6 
pH-sensitive (PEG-
PMMI-CholC6) 
168.3 ± 22.6 0.21 ± 0.2 -12.1 ± 1.9 70.9 ± 1.5 
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formed on the surface of niosomes 
(Dadashzadeh et al., 2010; Sadzuka and 
Hirota, 1997; Shehata et al., 2008). 
 
In vitro drug release study 
To assay pH-sensitivity of prepared nio-
somes, in-vitro release study was performed 
at two different pHs (7.4 and 6.5). Figure 2 
indicates that the cumulative drug release of 
conventional niosomes at pH 7.4 over 24 hrs 
(D24h) was significantly higher than the 
both types of pH-sensitive niosomes. In ad-
dition, the drug release rate from MTO-
loaded PEG-PMMI-CholC6 bearing nio-
somes was significantly lower than CHEMS-
based niosomes. On the other hand, at pH 
6.5, both types of pH-sensitive niosomes re-
leased higher level of MTO over 24 hrs 
compared to pH 7.4, demonstrating suitable 
pH-sensitivity of these two types of nio-
somes. In the case of PEG-PMMI-CholC6 
and CHEMS bearing niosomes, at pH 7.4, 
lower than 20 % and 10 % of the loaded 
MTO was released in 24 hrs, while at lower 
pH, a considerable increase was found in the 
release rate (65.4 and 70.2 %) indicating that 
these MTO-loaded PEG-PMMI-CholC6 and 
CHEMS-based niosomes may be suitable for 
intracellular drug delivery and drug delivery 
in cancerous tissues with mild acidic envi-
ronment. These findings are in accordance 
with our preliminary investigation which 
showed that drug release rate from PEG-
PMMI-CholC6 bearing micelles at pH 7.4 
was slower than pH 6.5 (Ghanbarzadeh et 
al., 2013a).  
 
 
Figure 2: Cumulative drug release from different 
types of niosomes at pHs 6.5 and 7.4 
PH-sensitivity of prepared niosomes in 
plasma was assessed by in-vitro release 
study of MTO from pH-sensitive niosomes 
in pHs 6.5 and 7.4 following 1 hr incubation 
in human plasma (50%, v/v) (Figure 3). The 
cumulative percent of released MTO from 
PEG-PMMI-CholC6 niosomes in pH 7.4 in-
creased compared to non-incubated nio-
somes, however this increase was not signif-
icant (P>0.05). Conversely, CHEMS-based 
niosomes after 1 hr incubation in plasma lost 
their pH-sensitivity property fairly and re-
leased higher percent of MTO at pH 7.4 
compared to those were not in contact with 
plasma. In contrast, as it was shown in Fig-
ure 3, after incubation in plasma lowering 
the pH value to 6.5 caused an increase in the 
release rate of MTO from PEG-PMMI-
CholC6 niosomes from 15.6 % at pH 7.4 to 
80.2 % at pH 6.5 and this indicates the sta-
bility of pH-sensitive property of niosomes 
after being in contact with plasma proteins. 
The difference between released drug at two 
pHs, before and after incubation in plasma 
was not significant. However, after incuba-
tion in plasma, the cumulative percent of re-
leased drug over 24 hrs from CHEMS-based 
niosomes did not differ significantly in two 
pHs.  
 
 
Figure 3: In vitro drug release of two types of 
pH-sensitive niosomes at pH 6.5 and 7.4 follow-
ing 1 h incubation in human plasma 
 
 
These data indicated that pH-sensitive 
property of PEG-PMMI-CholC6 based nio-
somes would be preserved in the blood and 
these types of niosomes could be stable in 
EXCLI Journal 2015;14:21-32 – ISSN 1611-2156 
Received: November 26, 2013, accepted: January 07, 2014, published: January 06, 2015 
 
 
27 
neutral pH and release MTO just in the slight 
acidic environments, where often present in 
tumor tissue or in intracellular acidic endo-
somal compartment. While the CHEMS-
based niosomes lasted this property and be-
came unstable in plasma and released their 
cargo in the circulation. Therefore, in order 
to use in vivo, they should be protected in 
blood stream from opsonization and reticu-
loendothelial system. In this light, our previ-
ous unpublished study verified that using 
PEG-cholesterol instead of cholesterol could 
also preserve the pH-sensitivity property of 
niosomes after incubation in plasma. There-
fore, plasma stable carriers can release the 
drugs at the target sites without wasting them 
during the circulation and can be promising 
carriers for intravenous delivery systems. 
 
Physicochemical stability study of  
niosomes  
Prepared niosomes were stored at 4 °C 
and 25 °C for a period of 3 months. The par-
ticle size distribution, zeta potential, entrap-
ment efficiency percent and drug content of 
the MTO-loaded niosomes were analyzed at 
the end of each month and presented in Ta-
ble 3.  
Normally, vesicles are at risk of aggrega-
tion, fusion and leaking in ambient tempera-
ture. However, storage at refrigerator tem-
perature minimizes the niosomes physical 
instability. Prepared niosomes were found to 
be generally stable in terms of aggregation or 
fusion, where particle size and zeta potential 
of niosomal formulation did not differ signif-
icantly after three months storage at 4 °C 
(P>0.05). On the other hand, storing at ambi-
ent temperature for three months resulted in 
an increase in particle size of all three types 
of niosomes (P<0.05).  
There was also no significant change in en-
trapment efficiency percent of the MTO nio-
somes after 3 months storage at 4 °C 
(P>0.05, Table 3). Mean initial EE% of three 
types of niosomes were 71.9 ± 2.3, 
73.2 ± 1.6 and 70.9 ± 1.5 % and after three 
months storage at 25 °C, average EE% of 
MTO in niosomal formulations were found 
to be 58.1±2.6, 59.4±3.2 and 57.3±2.6 %, 
respectively. Therefore, niosomes could be 
an effective carrier to minimize drug leakage 
from carrier at refrigerator temperature 
where higher percentage of drug was main-
tained in niosomal formulations compared to 
those stored at ambient temperature. This is 
predictable due to the fact that the higher 
temperatures resulted in higher fluidity of 
bilayers and as a result higher drug leakage 
(Angelini et al., 2011; Cho et al., 2007; 
Ghanbarzadeh et al., 2013b; Shimanouchi et 
al., 2009). 
To evaluate chemical stability of MTO 
niosomes, the drug content of niosomes was 
analyzed after three months storage at both 
refrigerator and ambient temperatures. Re-
sults revealed that MTO was relatively stable 
at niosomes stored at refrigerator conditions 
compared to room temperature. After three 
months, the mean MTO contents of nio-
somes were 87.1 % and 70.8 %, at 4 °C and 
25 °C, respectively. Generally, physico-
chemical stability study results indicated that 
keeping the vesicular products in refrigerated 
condition minimizes the physicochemical 
instability problems of vesicles. 
 
 
Table 3: Stability of prepared vesicles during storage at 4 °C and 25 °C for three months 
Niosome type Particle size (nm)±SD Zeta potential (mV)  
± SD 
Encapsulation effi-
ciency % ± SD 
Chemical 
stability 
(%) ± SD Initial After 3 
months 
Initial After 3 
months 
Initial After 3 
months 
Convention-
al 
4 °C 
186.3±26.3 
195.3.2±9.8 
-20.6±0.3 
-17.3±0.8 
71.9±2.3 
67.2±2.5 89.2±1.2 
25 °C 241.6±12.3 -16.8±1.0 58.1±2.6 72.6±2.8 
pH-sensitive 
(CHEMS) 
4 °C 
156.6±16.3 
175.2±18.2 
-16.6±0.5 
-14.9±0.9 
73.2±1.6 
68.2±2.4 86.9±3.4 
25 °C 221.3±13.5 -13.1±1.2 59.4±3.2 70.2±2.5 
pH-sensitive 
(PEG-PMMI-
CholC6) 
4 °C 
168.3±22.6 
167.9±13.8 
-12.1±1.9 
-10.7±1.8 
70.9±1.5 
65.3±2.9 85.2±1.9 
25 °C 232.6±42.3 -8.9±0.4 57.3±2.6 69.8±3.9 
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Plasma stability  
Serum proteins can destabilize pH-
sensitive vesicles and partially detach the 
copolymer from the lipid bilayers. Particle 
size and drug leakage of MTO-loaded PEG-
PMMI-CholC6 niosomes were measured af-
ter one hour incubation in 50 % (v/v) human 
plasma. Results showed that incubation in 
plasma dose not significantly change nio-
somes size and encapsulated drug percent. 
The change of particle size and the drug loss 
or the leakage from niosomes were lower 
than 11 % and 30 %, demonstrated the sta-
bility of PEG-PMMI-CholC6-based nio-
somes in plasma which is considered to be 
due to the change of PEG on the surface of 
niosome. However, in CHEMS-based nio-
somes, incubation in plasma caused an in-
crease in drug leakage and particle size 
growth, (P<0.05) (data not shown). 
The plasma stability study and release 
profile of MTO-loaded PEG-PMMI-CholC6 
niosomes, after incubation in plasma, indi-
cated the stability of pH-sensitive property of 
MTO-loaded PEG-PMMI-CholC6 niosomes. 
 
Antiproliferative study  
Cytotoxicity activity of conventional and 
both types of pH-sensitive niosomes with 
three concentrations were compared with 
corresponding blank niosomes on OVCAR-
3, MCF-7 and HUVEC cell lines (Figures 4-
6, respectively). Cell viability was expressed 
as the ratio of the levels of formazan pro-
duced by treated cells to those produced by 
control (non-treated) cells. As it was shown, 
the control blank niosomes of each one did 
not display any significant cytotoxicity on 
any of cell lines (P>0.05) compared to non-
treated groups. However, viability of 
OVCAR-3 and MCF-7 cells treated with 
both types of MTO-loaded pH-sensitive nio-
somes and conventional niosomes signifi-
cantly decreased compared to respective 
blank niosomes. Non-viable OVCAR-3 cell 
count increased up to 33.83, 72.26 and 
78.30 % in the case of conventional, 
CHEMS bearing pH-sensitive niosomes and 
PEG-PMMI-CholC6-based pH-sensitive nio-
somes containing 200 µmol MTO, respec-
tively. Both types of pH-sensitive MTO nio-
somes had the higher antiproliferative activi-
ties (P<0.05) compared to conventional nio-
somes in each three concentrations. 
 
Figure 4: Cytotoxicity effect of MTO niosomes on MCF-7 cell line. Blank conventional niosomes (C-
N.Blank), blank CHEMS niosomes (CHEMS-N.Blank), blank PEG-PMMI-CholC6 niosomes (PEG-
PMMI-CholC6-N.Blank), MTO-loaded conventional niosome (C-N+MTO), MTO-loaded CHEMS nio-
somes (CHEMS-N+MTO) and MTO-loaded PEG-PMMI-CholC6 niosome (PEG-PMMI-CholC6-N+ 
MTO). (Data are the mean values of three replications, *P<0.05, **P<0.01 and ***P<0.001 compared 
with C-N+MTO). 
EXCLI Journal 2015;14:21-32 – ISSN 1611-2156 
Received: November 26, 2013, accepted: January 07, 2014, published: January 06, 2015 
 
 
29 
 
 
Figure 5: Cytotoxicity effect of MTO niosomes on OVCAR-3 cell line. Blank conventional niosomes 
(C-N.Blank), blank CHEMS niosomes (CHEMS-N.Blank), blank PEG-PMMI-CholC6 niosomes (PEG-
PMMI-CholC6-N.Blank), MTO-loaded conventional niosome (C-N+MTO), MTO-loaded CHEMS nio-
somes (CHEMS-N+MTO) and MTO-loaded PEG-PMMI-CholC6 niosome (PEG-PMMI-CholC6-N+ 
MTO). (Data are the mean values of three replications, *P<0.05, **P<0.01 and ***P<0.001 compared 
with C-N+MTO). 
 
 
Figure 6: Cytotoxicity effect of MTO niosomes on HUVEC cell line. Blank conventional niosomes (C-
N.Blank), blank CHEMS niosomes (CHEMS-N.Blank), blank PEG-PMMI-CholC6 niosomes (PEG-
PMMI-CholC6-N.Blank), MTO-loaded conventional niosome (C-N+MTO), MTO-loaded CHEMS nio-
somes (CHEMS-N+MTO) and MTO-loaded PEG-PMMI-CholC6 niosome (PEG-PMMI-CholC6-N+ 
MTO). (Data are the mean values of three replications, *P<0.05,**P<0.01 and ***P<0.001 compared 
with C-N+MTO). 
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In contrast, compared to both types of 
pH-sensitive niosomes, conventional nio-
somes displayed stronger cytotoxicity on 
HUVEC cells, as a healthy and control cell 
line, than OVCAR-3 and MCF-7 cell lines 
(P<0.05). 
The results of MTT test confirmed the 
pH-sensitivity of both CHEMS and PEG-
PMMI-CholC6 bearing niosomes, where 
these niosomes had higher cytotoxicity on 
cancer cell lines, compared to the normal 
cells. This property is advantageous due to 
the reduction of cytotoxicity of anti-cancer 
drugs on healthy cells and resulting side ef-
fects. 
 
CONCLUSIONS 
The mechanism of many anticancer 
agents currently used currently for tumor 
treatment is based on cytotoxic effects. The 
non-target toxicity of chemotherapy is a ma-
jor undesirable side effect that limits dose 
and therapeutic window. The method which 
is using polymers in order to modify the sur-
faces of vesicles has been studied as a way to 
increase the sensitivity and stability of vesi-
cles. The addition of polymers can also ex-
hibit in vivo prolonged circulation times and 
increase drug accumulation in tumors. In the 
present work, two types of pH-sensitive nio-
somes were prepared by using two choles-
terol derivatives. Both niosomal formula-
tions showed pH-sensitivity in vitro. Plasma 
stable niosomes were developed to improve 
the efficiency of the Mitoxantrone as anti-
tumor drug and the effectiveness of the vesi-
cles as a delivery system was studied. These 
niosomes were stable at physiological pH but 
they released their contents after being ex-
posed to the acidic pH of the tumor tissues. 
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